Clinical trial readout dates for BioMarin Pharmaceutical Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2027.
| Phase 1/2 BMN 351 Duchenne Muscular Dystrophy · NCT06280209 | April 2027 Ongoing |
| Phase 1/2 BMN 307 Phenylketonuria (PKU) · NCT04480567 | December 2027 Ongoing |
| Phase 2 BMN 111 Achondroplasia · NCT02724228 | December 2027 Ongoing |
| Phase 2 vosoritide Achondroplasia · NCT04554940 | December 2027 Ongoing |
| Phase 2 Vosoritide Hypochondroplasia · NCT07126262 | June 2028 Recruiting |
| Phase 1/2 Dose 1 of BMN 331 Hereditary Angioedema; HAE · NCT05121376 | November 2028 Ongoing |
| Phase 2/3 BMN 333 Achondroplasia · NCT07441876 | June 2029 Recruiting |
| Phase 3 BMN 111 Achondroplasia · NCT03424018 | June 2031 Ongoing |
BioMarin Pharmaceutical Inc. reported $736M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). Its net loss for that quarter was $123M; at that rate the cash would last about 6 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-02 |